Intrexon | XON - Pre Tax Profit


Intrexon reported $-60.48M in Pre-Tax Profit for its fiscal quarter ending in June of 2024.





Pre Tax Profit Change Date
Agenus USD -10.61M 263.52M Dec/2025
Alaunos Therapeutics USD -7.84M 633K Dec/2023
Amgen USD 1.51B 2.41B Dec/2025
Anika Therapeutics USD 764K 3M Dec/2025
Arrowhead Research USD 28.27M 7.85M Dec/2025
AstraZeneca USD 3.91B 1.28B Mar/2026
Bristol-Myers Squibb USD 1.47B 1.64B Dec/2025
Gilead Sciences USD 2.08B 1.56B Dec/2025
GlaxoSmithKline GBP 2.14B 919M Mar/2026
Heron Therapeutics USD -2.95M 14.54M Dec/2025
Incyte USD 343.6M 46.34M Mar/2026
Intrexon USD -60.48M 27.09M Jun/2024
Karyopharm Therapeutics USD -39.9M 9.01M Dec/2025
Ligand Pharmaceuticals USD 56.78M 84.36M Dec/2025
MacroGenics USD -14.93M 31.75M Dec/2025
MannKind USD -16.37M 4.56M Mar/2026
Merck USD 3.42B 3.32B Dec/2025
Novartis USD 3.84B 802M Mar/2026
Rigel Pharmaceuticals USD -1.03M 7.22M Jun/2024
Roche Holding CHF 4.79B 3.01B Jun/2025
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Thermo Fisher Scientific USD 2.12B 295M Dec/2025
Veracyte USD 29.97M 10.66M Mar/2026
Xencor USD -128.64M 124.37M Mar/2026